Program
diacerein
Also written as “Diacerein”, “diacerein 1% ointment” and “AC-201”.
Its studies are mostly in Osteoarthritis, Knee · Epidermolysis Bullosa Simplex · Epidermolysis Bullosa · Psoriasis · Gout, led by 7 companies.
Drug pageDiacerein: every studyMany companies study it; this page follows only the 21 they lead. All 37 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Castle Creek Pharmaceuticalsits history only | 70 open or running | phase 2since May 10, 2017 | May 10, 2017 | none ahead |
| TWi Biotechnologyits history only | 61 open or running | phase 3since Sep 12, 2023 | Jan 11, 2011 | none ahead |
| Wockhardtits history only | 30 open or running | phase 4since Feb 26, 2007 | Feb 26, 2007 | none ahead |
| TRB Chemedicaits history only | 21 open or running | phase 3since Mar 16, 2020 | Jun 28, 2010 | Dec 31, 2026phase 3 · NCT04318041 |
| Accro Bioscience (Suzhou)its history only | 10 open or running | phase 2since May 7, 2025 | May 7, 2025 | none ahead |
| ANS Pharmaits history only | 10 open or running | phase 2since Jun 27, 2017 | Jun 27, 2017 | none ahead |
| TRB Chemedica Internationalits history only | 10 open or running | phase 3since Feb 10, 2016 | Feb 10, 2016 | none ahead |
Also a collaborator on its studies: ArthroLab and TKL Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Feb 26, 2007.
- Jan 11, 2011TWi Biotechnology’s first study: phase 2 study in Diabetes Mellitus, Type 2New to TWi BiotechnologyTWi Biotechnology · NCT01276106 · 259 enrolled · United States, Taiwan
- Oct 19, 2012Phase 2 study in HyperuricemiaTWi Biotechnology · NCT01712204 · 82 enrolled · Taiwan
- Nov 6, 2014Phase 2 study in GoutTWi Biotechnology · NCT02287818 · 127 enrolled · Taiwan
- Feb 10, 2016TRB Chemedica International’s first study: phase 3 study in OsteoarthritisNew to TRB Chemedica InternationalTRB Chemedica International · NCT02688400 · 380 enrolled · Austria, Belgium, Canada and more
- May 10, 2017Castle Creek Pharmaceuticals’ first study: phase 2 study in Epidermolysis Bullosa SimplexNew to Castle Creek PharmaceuticalsCastle Creek Pharmaceuticals · NCT03154333 · 54 enrolled · United States, Australia, Austria and more
- Jun 27, 2017ANS Pharma’s first study: phase 2 study in Diabetes ComplicationsNew to ANS PharmaANS Pharma · NCT03208309 · 40 enrolled · Brazil
- Sep 14, 2017Phase 2 study in Pemphigoid, BullousTWi Biotechnology · NCT03286582 · 10 enrolled · Taiwan
- Dec 19, 2017Phase 2 study in Epidermolysis BullosaCastle Creek Pharmaceuticals · NCT03389308 · 51 enrolled · United States
- Jan 30, 20182 phase 1 studies in HealthyCastle Creek Pharmaceuticals · NCT03472547, NCT03472534
- Mar 5, 20183 phase 1 studiesCastle Creek Pharmaceuticals · NCT03473197, NCT03473184, NCT03472287
- Mar 8, 2018Phase 2 study in Inherited Epidermolysis BullosaTWi Biotechnology · NCT03468322 · 9 enrolled · Taiwan
- Mar 16, 2020Phase 3 study in Osteoarthritis, KneeTRB Chemedica · NCT04318041 · 128 enrolled · Thailand
- Sep 12, 2023Phase 3 study in Epidermolysis Bullosa SimplexTWi Biotechnology · NCT06073132 · 80 enrolled · United States, Australia, Austria and more
- May 7, 2025Accro Bioscience (Suzhou)’s first study: phase 2 study in Plaque PsoriasisNew to Accro Bioscience (Suzhou)Accro Bioscience (Suzhou) · NCT06972888 · 145 enrolled · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Osteoarthritis, KneeTRB Chemedica · NCT04318041
TargetBeta
“AC-203 (diacerein 1% ointment) is a topical formulation of diacerein, well-known for its ability to inhibit IL-1β and other proinflammatory cytokines.”study text, by rule · the study
Other programs on IL1B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lutikizumab | AbbVie | phase 3 | 12 |
| arumakimig | Novartis | phase 2 | 7 |
| ABBV-1451 | AbbVie | phase 1 | 1 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06972888Plaque Psoriasis · China | 2 | Completed | Accro Bioscience (Suzhou) | Mar 7, 2025 | 145 |
| NCT06073132Epidermolysis Bullosa Simplex · United States, Australia, Austria and more | 3 | Active, not recruiting | TWi Biotechnology | Jun 10, 2026 | 80 |
| NCT04318041Osteoarthritis, Knee · Thailand | 3 | Active, not recruiting | TRB Chemedica | Dec 31, 2026 | 128 |
| NCT03472287Epidermolysis Bullosa · United States | 1 | Completed | Castle Creek Pharmaceuticals | Jan 31, 2019 | 11 |
| NCT03468322Inherited Epidermolysis Bullosa · Taiwan | 2 | Completed | TWi Biotechnology | Apr 9, 2019 | 9 |
| NCT03473197Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Mar 9, 2018 | 61 |
| NCT03473184Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Dec 15, 2017 | 34 |
| NCT03472547Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Mar 3, 2018 | 234 |
| NCT03472534Healthy · United States | 1 | Completed | Castle Creek Pharmaceuticals | Jan 30, 2018 | 46 |
| NCT03389308Epidermolysis Bullosa · United States | 2 | Completed | Castle Creek Pharmaceuticals | Apr 17, 2020 | 51 |
| NCT03286582Pemphigoid, Bullous · Taiwan | 2 | Terminated | TWi Biotechnology | Dec 25, 2018 | 10 |
| NCT03208309Diabetes Complications · Brazil | 2 | Completed | ANS Pharma | Aug 2015 | 40 |
| NCT03154333Epidermolysis Bullosa Simplex · United States, Australia, Austria and more | 2 | Terminated | Castle Creek Pharmaceuticals | Oct 15, 2018 | 54 |
| NCT02688400Osteoarthritis · Austria, Belgium, Canada and more | 3 | Completed | TRB Chemedica International | Jun 26, 2018 | 380 |
| NCT02287818Gout · Taiwan | 2 | Completed | TWi Biotechnology | Oct 27, 2016 | 127 |
| NCT01712204Hyperuricemia · Taiwan | 2 | Completed | TWi Biotechnology | Sep 2013 | 82 |
| NCT01276106Diabetes Mellitus, Type 2 · United States, Taiwan | 2 | Completed | TWi Biotechnology | Feb 2012 | 259 |
| NCT01264211Arthritis, Rheumatoid · Thailand | 2 | Completed | TRB Chemedica | Jun 2012 | 40 |
| NCT00451360Osteoarthritis, Hip · France | 3 | Completed | Wockhardt | 500 | |
| NCT00445276Osteoarthritis, Knee · France | 4 | Completed | Wockhardt | Sep 2006 | 500 |
| NCT00440661Osteoarthritis · Canada | 4 | Completed | Wockhardt | Oct 2008 | 96 |
How it is read
Names in the registry
- “Diacerein”, 4 entries
- “diacerein 1% ointment”, 4 entries
- “AC-201”, 3 entries
- “AC-203”, 2 entries
- “Diacerein 1% ointment”, 2 entries
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 3 studies
- Epidermolysis Bullosa Simplex, 3 studies
- Epidermolysis Bullosa, 2 studies
- Psoriasis, 1 study
- Gout, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.